The Generic Drugs Market Accounts for 50% of All Prescriptions Filled in The US.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c38921) has announced the addition of Combating Generics - Pharmaceutical Brand Defense for 2007 to their offering. Maximize drug revenues by preparing for patent expiry and generic competition early in product lifecycles. Generic drugs now account for more than 50% of all prescriptions filled in the US and more than $40 billion in prescription sales worldwide. More than $80 billion worth of global blockbuster drugs face US patent expiration by 2008. Use this report to better understand and act on the range of options available to branded companies defending products against generic threats. The information contained within is gathered from individuals involved in product lifecycle management, brand management and marketing, portfolio management, market research, and other functions associated with long-term brand viability. Findings integrate primary and secondary information to present readers with a comprehensive look at current generics defense efforts, including the following strategies: --Defensive pricing --Increased marketing and promotion --Approval for additional indications --Next-generation product launches --Patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. --Authorized generics and corporate generics subsidiaries --Pediatric extensions --Rx-to-OTC switching --Measure resource levels against other companies' budgets and staffing support for anti-generics efforts, and review case studies of anti-generic battles, discussions of legal and regulatory developments, and profiles of leading generics manufacturers. Topics Covered Executive Summary Profiled Companies Managing Generics Threats: Five Principles for Success Generics Defense Strategies, Resources and Timing Generics Defense Strategies: Past and Future Prominence Budgets and Staffing Strategy Breakdown: Prominence and Timing of Generics Defense Strategies Retaining Market Share with Lifecycle Management Secure Revenue Streams with Line Extensions Blurring the Lines: Pharma-Generics Deal-Making and Market Crossover Strategies Rx-To-OTC Switching Other Market Share Retention Strategies Key Trends And Generic Industry Developments Recent Regulatory Developments Generic Industry Trends Follow-on Biologics Generic Company Profiles Actavis Andrx Barr Laboratories Baxter Healthcare Dr. Reddy's Laboratories Dr. Reddy’s Laboratories Ltd. (Reddy's), founded in 1984 by Dr. K. Anji Reddy, has become India’s third biggest pharmaceutical company. Reddy had worked in the publicly-owned Indian Drugs and Pharmaceuticals Ltd. Hospira Mylan Laboratories Par Pharmaceuticals Ranbaxy Laboratories Ranbaxy Laboratories Limited is an Indian company incorporated in 1961. It is India's largest pharmaceutical company. It exports its products to 125 countries with ground operations in 46 and manufacturing facilities in seven countries. Roxane Laboratories Sandoz TEVA TEVA Tucson Electric Vehicle Association Pharmaceuticals Watson Pharmaceuticals Watson Pharmaceuticals, Incorporated (NYSE: WPI) is the 5th largest pharmaceutical company in the United States based on number of prescriptions dispensed. Based in Corona, California, Watson's Generics division markets over 150 pharmaceutical product families, including one of the Executive Summary: Charts and Tables Companies Profiled in Primary and Secondary Research: - 3M Pharmaceuticals - Abbott - Actavis - Advancis Pharmaceutical Corp - Alpharma - Alza - Amgen - Amphastar Pharmaceuticals - Andrx - Apotex - Argenta Discovery Limited - Astellas - AstraZeneca - Auxilium - Avanir Pharmaceuticals - Barr - Baxter - Bayer - BCBS BCBS Blue Cross/Blue Shield BCBS Basel Committee on Banking Supervision BCBS Barre Center for Buddhist Studies BCBS Bay City Baptist School BCBS Bishop Cotton Boys School (Bangalore, India) BCBS Bar Code Business Software - Berlex - Biovail - Boehringer-Ingelheim - Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were - Cephalon Ceph´a`lon n. 1. (Zool.) The head. - Dr. Reddy's Laboratories - Duramed Pharmaceuticals - Eisai - Elan - Eli Lilly - Endeavor Pharmaceuticals - Ferring B.V. - First Horizon Pharmaceutical - Forest Laboratories - Galen - Genentech - Geneva Geneva, canton and city, Switzerland Geneva (jənē`və), Fr. Genève, canton (1990 pop. 373,019), 109 sq mi (282 sq km), SW Switzerland, surrounding the southwest tip of the Lake of Geneva. - Genpharm - Genzyme - GlaxoSmithKline - Global Prior Art - Greenstone green·stone n. Any of various altered basic igneous rocks colored green by chlorite, hornblende, or epidote. greenstone Noun NZ a type of green jade used for Maori carvings and ornaments Ltd. - Hospira - Interpharma Asia Pacific - Janssen - Janssen-Ortho - Johnson & Johnson - King Pharmaceuticals - Knoll Pharmaceuticals - Kos Pharmaceuticals - KV Pharmaceuticals - LEO Pharmaceuticals - Maruishi Pharmaceutical - Merck and Co. - Merck KGaA - MN Pharmaceuticals - Momenta Pharmaceuticals - Monarch - Mylan - Nabi Biopharmaceuticals - NexMed - Nihon Pharmaceutical - Novartis - Novo Nordisk - Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. - Ortho-McNeil - Otsuka - PAM Kft - Par - Pfizer - PLIVA Croatie Ltd - Procter & Gamble - Purdue Pharma - Ranbaxy - Rheoscience - Roche - Roxane Laboratories - Sandoz - Sanofi-Aventis - Schering Plough - Shire - Solvay - Synaptech - Takeda - Teva - Unimed - Ventiv Health - Vernalis plc - Watson - Wellpoint Health Networks (BCBS) - Wyeth - Xcel For more information visit http://www.researchandmarkets.com/reports/c38921 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion